Johnson & Johnson (NYSE:JNJ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET
Company Participants
Jessica Moore - Vice President, Investor Relations
Joaquin Duato - Chairman & Chief Executive Officer
Joe Wolk - Executive Vice President, Chief Financial Officer
Erik Haas - Head, Worldwide Litigation
Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine
John Reed - Executive Vice President, Innovative Medicine, R&D
Conference Call Participants
Chris Schott - JPMorgan
Larry Biegelsen - Wells Fargo
Louise Chen - Cantor Fitzgerald
Terence Flynn - Morgan Stanley
Danielle Antalffy - UBS
Shagun Singh - RBC Capital Markets
Vamil Divan - Guggenheim Securities
Jayson Bedford - Raymond James
Operator
Good morning, and welcome to Johnson & Johnson's Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions]
I would now like to turn the conference call over to Johnson & Johnson. You may begin.
Jessica Moore
Hello, everyone. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of the third quarter results and our full year financial outlook for 2024.
A few logistics before we get into the details. As a reminder, you can find additional materials, including today's presentation and associated schedules on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording and are subject to certain risk and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2023 Form 10-K, which is available at investor.jnj.com and on the SEC's website.
Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.
Moving to today's agenda. Joaquin Duato, our Chairman and CEO, will kick us off with opening remarks and highlight key catalysts within the segments. I will review the third quarter sales and P&L results for the enterprise, as well as highlights related to our two businesses. Joe Wolk, our CFO, will then provide an overview of our pipeline advancements, cash position, capital allocation priorities and guidance for 2024, as well as qualitative considerations for 2025. Jennifer Taubert, John Reed and Tim Schmid, our Innovative Medicine and MedTech leaders, will be joining us for Q&A. To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes.